1470169-11-9

Basic information

• Product Name: C₃₁H₃₃N₃O₆
• CAS NO: 1470169-11-9
• Molecular Weight: 543.62
• Mol File: 1470169-11-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₃₁H₃₃N₃O₆(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₁H₃₃N₃O₆(1470169-11-9)
• EPA Substance Registry System: C₃₁H₃₃N₃O₆(1470169-11-9)

Safety Data

• Hazardous Substances Data: 1470169-11-9(Hazardous Substances Data)

Upstream product

• 1470169-09-5 C₃₁H₃₂N₂O₇ 
• 1470169-07-3 C₂₂H₂₁NO₅ 
• 1470169-05-1 C₂₂H₂₃NO₆ 
• 1470169-03-9 1,5-dimethyl 2-azido-3,3-dimethylpentanedioate 
• 19184-67-9 methyl 3,3-dimethylglutarate 
• 4839-46-7 3,3-Dimethylglutaric acid 

Relevant articles and documents

A general method for making peptide therapeutics resistant to serine protease degradation: Application to dipeptidyl peptidase IV substrates

Bioactive peptides have evolved to optimally fulfill specific biological functions, a fact which has long attracted attention for their use as therapeutic agents. While there have been some recent commercial successes fostered in part by advances in large-scale peptide synthesis, development of peptides as therapeutic agents has been significantly impeded by their inherent susceptibility to protease degradation in the bloodstream. Here we report that incorporation of specially designed amino acid analogues at the P1′ position, directly C-terminal of the enzyme cleavage site, renders peptides, including glucagon-like peptide-1 (7-36) amide (GLP-1) and six other examples, highly resistant to serine protease degradation without significant alteration of their biological activity. We demonstrate the applicability of the method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activation protein α (FAPα), α-lytic protease (αLP), trypsin, and chymotrypsin. In summary, the "P1′ modification" represents a simple, general, and highly adaptable method of generating enzymatically stable peptide-based therapeutics.